Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia.
Continue reading "Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication" »
